Biocytogen Responds to Harbour BioMed's Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing
Biocytogen stands by its core values of independent innovation, respect for intellectual property, and a commitment to fair competition. The RenNano® platform is the result of independent, original R&D, based on Biocytogen's proprietary genome editing technologies. Its technical principles, design strategy, and IP scope are fundamentally different from the patents in dispute.
120 vs. 9 – A Significant Technical Divide of RenNano® Platform; Biocytogen Will Resolutely Take Legal Actions to Protect Its Rights
The RenNano® platform employs a large-fragment knock-in strategy that incorporates over 120 human V genes in situ, enabling a complete and functional human heavy chain antibody repertoire. In stark contrast, Harbour BioMed's HCAb platform introduces only 9 V genes through a small-fragment transgenic approach. This key difference reflects not only divergent technical strategies but also the depth, innovation, and translational potential of Biocytogen's antibody discovery platforms.
The decision referenced in Harbour BioMed's PR involves a procedural ruling on jurisdiction only and does not address the substance of the patent infringement case. Furthermore, the CNIPA's affirmation of patent validity is a routine administrative process that does not imply infringement. The underlying lawsuit has not yet entered the trial phase.
Biocytogen is currently evaluating all legal options and will resolutely defend its IP rights and scientific reputation. The RenNano® platform has been fully validated and is supported by a robust portfolio of domestic and international patents, clearly documenting its originality and independence.
We remain confident in:
The technical integrity and legal foundation of the RenNano® platform;
The non-infringement of any third-party IP;
Our continued leadership in antibody discovery and therapeutic innovation.
According to public records, the Chinese patent related to Harbour BioMed's HCAb platform is set to expire on July 22, 2025, further underscoring the short-sighted nature of any speculative claims. Regardless, Biocytogen will continue to uphold its rights, ensure business continuity, and deliver transformative technologies for global partners and patients.
Any misleading allegations or speculative narratives will not deter our team from advancing the RenMice® platform series with world-class innovation and delivering on our mission to accelerate therapeutic discovery.
Key Technical Differences Between Biocytogen's RenNano® Platform and Harbour BioMed's HCAb Platform
Biocytogen RenNano® Platform: Uses large-fragment knock-in technology to replace mouse genes with over 120 human V genes in situ, resulting in a full and functional human heavy chain variable region genomic repertoire.
Harbour BioMed HCAb Platform: Introduces only 9 V genes using small-fragment transgenic approaches.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
China-Made Tesla Sales Rose in June. Is This the Lifeline TSLA Stock Needed?
Tesla (TSLA) shares are pushing to the upside on Wednesday after data from the China Passenger Car Association confirmed the automaker's sales of China-made electric vehicles increase 0.8% on a year-over-year basis in June. Though modest, the increase is significant given it snapped TSLA's eight-month losing streak in one of its biggest global markets. Despite today's gain, Tesla stock is down 13% versus its high set in the final week of May. Is UnitedHealth Stock a Buy, Sell, or Hold for July 2025? Is MicroStrategy Stock a Buy, Sell, or Hold for July 2025? Circle Just Applied for a Bank Charter. How Should You Play CRCL Stock Here? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. While China data sure is positive for investors, it's not very likely to help Tesla shares extend gains further since the automaker's overall deliveries for the second quarter came in down 14% year-over-year on Wednesday. The company delivered just 384,122 vehicles in its fiscal Q2, down significantly from 443,956 deliveries in the same quarter last year – reinforcing concerns that TSLA is losing market share to its Chinese rivals. Tesla Inc has recently had a successful launch of robotaxi services in Austin, but it's still reasonable to assume that continued weakness in the core EV business will make it incrementally difficult for TSLA stock to print new highs in the near term. According to Steve Westly, a former member of Tesla's board, the EV maker needs three things to unlock its path to sustainable share price recovery. Tesla must launch a lower-cost ($25,000) model to compete more aggressively with rivals. Tesla needs regulatory approval for its robotaxi in multiple cities to catch up with Waymo. Tesla has to rebrand itself – which means less politics, more products, and lower prices. Westly remains confident that TSLA has the technology to compete across all verticals, but unless it 'finds a higher gear' – this EV stock may continue to fail in delivering the kind of gains that investors have come to expect of it, he told CNBC in an interview today. Investors should note that Wall Street firms are no longer bullish on Tesla stock either. According to Barchart, the consensus rating on TSLA shares currently sits at 'Hold' only with the mean target of about $297 indicating potential downside of some 5% from here. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Business Wire
25 minutes ago
- Business Wire
Redfin Reports New Listings, Pending Sales Fall As Home Prices Hit Another All-Time High
SEATTLE--(BUSINESS WIRE)--(NASDAQ: RDFN) — The median U.S. home-sale price hit a record high during the four weeks ending June 29, but buyers are getting a bit of cost relief as mortgage rates decline. That's according to a new report from Redfin ( the technology-powered real estate brokerage. Redfin is taking a break from full analysis this week, but please see the tables and charts below for this week's housing-market data. For Redfin economists' takes on the housing market, please visit Redfin's ' From Our Economists ' page. Leading indicators Key housing-market data U.S. highlights: Four weeks ending June 29, 2025 Redfin's national metrics include data from 400+ U.S. metro areas, and are based on homes listed and/or sold during the period. Weekly housing-market data goes back through 2015. Subject to revision. Four weeks ending June 29, 2025 Year-over-year change Notes Median sale price $400,125 1.4% All-time high Median asking price $415,174 3.9% Median monthly mortgage payment $2,742 at a 6.67% mortgage rate 1.6% Lowest level in 4 months Pending sales 86,718 -3.2% Biggest decline in nearly 4 months New listings 99,921 -0.7% First decline in nearly 6 months Active listings 1,184,250 14.1% Smallest increase in over a year Months of supply 4.1 +0.8 pts. 4 to 5 months of supply is considered balanced, with a lower number indicating seller's market conditions Share of homes off market in two weeks 36.3% Down from 40% Median days on market 37 +5 days Share of homes sold above list price 28.4% Down from 32% Average sale-to-list price ratio 99.1% Down from 99.6% Expand To view the full report, including charts, please visit: About Redfin Redfin ( is a technology-powered real estate company. We help people find a place to live with brokerage, rentals, lending, and title insurance services. We run the country's #1 real estate brokerage site. Our customers can save thousands in fees while working with a top agent. Our home-buying customers see homes first with on-demand tours, and our lending and title services help them close quickly. Our rentals business empowers millions nationwide to find apartments and houses for rent. Since launching in 2006, we've saved customers more than $1.8 billion in commissions. We serve approximately 100 markets across the U.S. and Canada and employ over 4,000 people. Redfin's subsidiaries and affiliated brands include: Bay Equity Home Loans®, Rent.™, Apartment Guide®, Title Forward® and Walk Score®. For more information or to contact a local Redfin real estate agent, visit To learn about housing market trends and download data, visit the Redfin Data Center. To be added to Redfin's press release distribution list, email press@ To view Redfin's press center, click here.
Yahoo
30 minutes ago
- Yahoo
Bonacibo, Reflex, and Vancat Among Winners at 2025-2026 World Branding Awards Animalis Edition in Vienna
LONDON, July 03, 2025--(BUSINESS WIRE)--The 2025-2026 World Branding Awards Animalis Edition marked its fifth instalment, bringing together leading pet and animal brands from every corner of the globe. These brands were celebrated for their outstanding achievements, earning recognition as National, Regional, and Global Winners. The awards ceremony, held at Vienna's prestigious Hofburg Palace, welcomed winners across diverse categories, including pet food, retail, wellness, pet exhibitions, and aquatic products. Mounia Berrada-Gouzi expertly hosted the evening, which culminated in a grand celebration of brand excellence. "The Animalis Edition of the World Branding Awards recognises brands that have achieved the highest distinction—genuine recognition in the hearts and minds of consumers. Tonight, we honour those whose names resonate globally, whose values inspire loyalty, and whose presence defines excellence in the pet and animal industry," said Richard Rowles, Chairman of the World Branding Forum. Out of over 950 brands nominated by more than 80,000 consumers in a global online survey, only the top 105 brands from 25 countries achieved the coveted title of winner. Earning a World Branding Award is a significant achievement, solidifying their status as industry leaders. Proving their excellence and impeccable branding, the Global tier winners include Frontline (Germany), Kit Cat (Singapore), KONG (UK), Sheba (USA), and Whiskas (USA). Winners from Türkiye include Bonacibo, Reflex, and Vancat. Other National tier winners include Bamboodles (UK), Bok Dok (Thailand), CIAO (Japan), Cooper and Gracie (UK), Heads Up For Tails (India), Kaniva (Thailand), Kelly & Co's (Thailand), Nutriment Natural Treats (UK), Petio (Japan), Powercat (Malaysia), Pramy (Thailand), and Topbreed (The Philippines), to name a few. Regional tier winners include Alps Natural (Malaysia), EHEIM (Germany), and Hikari (Japan). These brands were voted as consumers' favourites in 4 or more countries across 3 or more areas in a specific geographic region. As the 2025-2026 World Branding Awards Animalis Edition concludes, the highly anticipated Global Edition of the World Branding Awards is set to return to the stage this November. For more information, visit ABOUT WORLD BRANDING AWARDS The World Branding Awards is the premier award of the World Branding Forum, a registered non-profit organisation. The awards recognise the achievements of some of the world's best brands. SOCIAL MEDIA Facebook: Twitter: Instagram: LinkedIn: View source version on Contacts EDITORIAL CONTACT Email: editorial@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
